30 Technology has been actively engaged in expanding its clinical team to drive its lead respiratory assets through multiple ongoing early phase clinical trials.
30 Technology expands its clinical team
read more
News
30 Technology receives regulatory approval for TASK tuberculosis Study in South Africa
30 Technology is delighted to report that this month we received full regulatory approval to start our Phase 2 trial in adults with newly diagnosed pulmonary tuberculosis (TB).
30 Technology Expands Its Scientific Team And Opens New Innovation Hub At Scale Space, Imperial College London
30 Technology is delighted to announce the opening of its new Innovation Centre in Scale Space – a part of Imperial College London’s White City campus located in the heart of West London.
30 Technology enters into a strategic Licencing Agreement to develop new treatments for multi-drug resistant tuberculosis
Thirty Technology joins the fight against antibiotic resistant infection.
30 Technology launches a critical clinical trial of RESP301 in cystic fibrosis patients with serious lung infections
RESP301 to combat antibiotic resistant/refractory infection in people with cystic fibrosis
Thirty Respiratory receives approval for multicentre post-exposure clinical trial of RESP301 to prevent transmission of COVID-19 in the community
Break-through new treatment to protect people at risk from COVID-19
30 Technology announces first patients enrolled in UK clinical trial (NOCoV2) for the treatment of COVID-19
Thirty Respiratory Ltd (“30 Technology”) announced today that the first patients have been enrolled in the multicentre Phase 2/3 NOCoV2 trial of its leading antiviral product, RESP301, as a treatment for patients hospitalised with COVID-19.